Sirnaomics
Gaithersburg · Founded 2007
About Sirnaomics
Sirnaomics is a clinical-stage biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology. The RNAi technology is used to discover and develop novel therapeutics with a focus on oncology, anti-fibrotic therapeutics, and viral infection. Its proprietary Polypeptide Nano-Particle (PNP) technology is used for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver. Sirnaomics was founded by Patrick Y. Lu and David M. Evans in 2007 and is based in Gaithersburg, Maryland.
Company Facts
- Founded: 2007
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $293.3M
- Funding stage: IPO
- Last round: Post-IPO Equity (Sep 2025)
- Ticker: hkg:2257
- Website: sirnaomics.com
- Phone: +113017401730
Industries & Categories
Biopharma, Biotechnology, Medical Device, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/sirnaomics-85154 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.